Verax Biomedical inks manufacturing agreement
Worcester-based Verax Biomedical Inc. has signed a 10-year agreement with British Biocell International to manufacture the Verax Platelet PGD(R) test, with the potential to produce as many as 50 million tests, and effectively creating a second manufacturing facility to handle Verax production.
The agreement comes on the heels of news that Abbott Diagnostics will distribute and market Verax's Platelet PGD Test, a disposable device allowing users to detect bacteria contaminants in platelets prior to transfusion. The American Association of Blood Banks requires that all of its members detect and limit contamination in platelets. Current methods are not always reliable, and take up to three days before results are available. The Verax device provides results within 30 minutes.
A substantial amount of demand for the product is anticipated, said Verax CEO Jim Lousararian. "We need a seasoned contract manufacturing partner like BBI who can meet this demand," he said. "We are so confident in the success of the Verax PGD Test that we are adding a second manufacturing facility to gear up to meet demand."
Clinical trials of the test are currently underway at University Hospitals Case Medical Center and the Cleveland Clinic in Cleveland, Ohio, as well as at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire.
WBJ Web Partners
Most Recent
Most Recent
0 Comments